Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT01872975

Active, not recruiting

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Stage II Breast Cancer | Stage IB Breast Cancer
NCT03958721

Completed

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Resistant Breast Cancer | Non-metastatic Invasive Breast Cancer
NCT04032080

Completed

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT03193853

Completed

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT05730010

Completed

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

Triple Negative Breast Cancer
NCT03464942

Completed

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC)

Breast Cancer
NCT04335006

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer
NCT03750240

Terminated

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

Breast Cancer | Triple Negative Breast Cancer
NCT03413761

Completed

Antioxidant Supplements, Genetics and Chemotherapy Outcomes

Node Negative Breast Cancer | Node Positive Breast Cancer
NCT02897050

Suspended

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Breast Cancer
NCT01880541

Completed

Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer (HYPNOSEIN)

Patients With Breast Cancer and Breast Surgery Requiring
NCT01831076

Completed

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer
NCT03894007

Terminated

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

HER2-positive Breast Cancer | Early-stage Breast Cancer
NCT02984683

Terminated

Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT02593227

Completed

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Breast Cancer
NCT04067102

Withdrawn

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Triple Negative Breast Cancer
NCT00542191

Terminated

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Breast Cancer
NCT02685059

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer
NCT04405505

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT04031703

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Breast Cancer
NCT04236310

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
NCT03058939

Withdrawn

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III
NCT03316794

Terminated

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Breast Cancer
NCT02470819

Withdrawn

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Metastatic Breast Cancer | Breast Tumor | Advanced Gynecologic Cancer
NCT02347163

Terminated

Pre-operative Zoledronate in Triple Negative Breast Cancer

Breast Cancer
NCT02364960

Terminated

Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT) (TARGIT)

Early Stage Breast Cancer | Breast Tumor | Neoplasm of the Breast
NCT01094184

Completed

A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer (BATMAN)

Breast Cancer
NCT00016549

Completed

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Breast Cancer
NCT00344071

Completed

Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia

Inflammatory Breast Cancer
NCT01186991

Completed

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Breast Cancer
NCT02338531

Withdrawn

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer (RHEA)

Breast Cancer
NCT02511847

Unknown

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Triple Negative Breast Cancer
NCT02681562

Unknown

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Breast Cancer | Triple Negative Breast Cancer
NCT02616848

Unknown

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Triple Negative Breast Cancer
NCT02595138

Active, not recruiting

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT01287624

Completed

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer
NCT01434420

Unknown

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Breast Cancer
NCT02001519

Completed

Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy (PACER)

Breast Cancer
NCT01969032

Completed

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT01333137

Terminated

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Breast Cancer
NCT02115152

Unknown

Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer

Stage II Breast Cancer | Stage III Breast Cancer
NCT01880385

Unknown

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer (Beva)

Inflammatory Breast Cancer
NCT00773669

Completed

Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007

Breast Cancer
NCT07222215

Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) (CAPELA)

Breast Cancer | Breast Neoplasms | Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen-receptor-positive Breast Cancer | ESR1 Gene Mutation | Hormone Receptor Positive Breast Cancer | HER2- Breast Cancer | ER Wildtype
NCT05190770

Completed

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

Breast Cancer | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage
NCT01042535

Completed

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer
NCT02760030

Completed

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Estrogen Receptor and/or Progesterone Receptor Positive
NCT03113825

Completed

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female Breast
NCT04086875

Active, not recruiting

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8
NCT03106077

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations